Mer­ck, Pfiz­er make a late — very late — ar­rival at the SGLT2 par­ty for di­a­betes

Mer­ck and Pfiz­er have land­ed an FDA ap­proval to start mar­ket­ing er­tugliflozin, mark­ing a late ar­rival for a ther­a­py that will now go toe-to-toe with some deeply en­trenched ri­vals in the SGLT2 niche.

The FDA not­ed the ap­proval on its site, hit­ting the green light for the sin­gle ther­a­py as well as com­bi­na­tions with Mer­ck’s Janu­via or met­formin, the stan­dard ther­a­py for di­a­betes. Cu­ri­ous­ly, though, the com­pa­nies have yet to put out a re­lease mark­ing the oc­ca­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.